BBB-targeting, protein-based nanomedicines for drug and nucleic acid delivery to the CNS

Biotechnology Advances

Volumn 33, Issue 2, 2015, Pages 277-287

  Peluffo, Hugo ^a,b   Unzueta, Ugutz ^c,d   Negro Demontel, María Luciana ^a,b   Xu, Zhikun ^c,d   Váquez, Esther ^c,d   Ferrer Miralles, Neus ^c,d   Villaverde, Antonio ^c,d  

^a INSTITUT PASTEUR DE MONTEVIDEO   (Uruguay)

^b DEPARTAMENTO DE BIOQUÍMICA   (Uruguay)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

Author keywords

Artificial viruses; BBB; Drug delivery; Gene therapy; Nanoparticles; Protein engineering; Recombinant proteins

Indexed keywords

AUTOMOBILE MANUFACTURE; BLOOD; CONTROLLED DRUG DELIVERY; DRUG DELIVERY; GENE THERAPY; NANOPARTICLES; NUCLEIC ACIDS; RECOMBINANT PROTEINS; VIRUSES;

ARTIFICIAL VIRUS; BIOLOGICAL LIMITATIONS; CENTRAL NERVOUS SYSTEMS; DRUG DELIVERY TOOLS; FUNCTIONAL PROTEINS; NUCLEIC ACID DELIVERIES; PROTEIN ENGINEERING; SYSTEMIC ADMINISTRATION;

TARGETED DRUG DELIVERY;

BLOOD; DRUG DEVELOPMENT; MEDICINE; NANOTECHNOLOGY; NERVOUS SYSTEM; NUCLEIC ACID; PROTEIN;

NANOPARTICLE; NUCLEIC ACID;

BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASES; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; GENE TRANSFER; HUMAN; NANOMEDICINE; PATHOLOGY;

BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASES; DRUG DELIVERY SYSTEMS; GENE TRANSFER TECHNIQUES; HUMANS; NANOMEDICINE; NANOPARTICLES; NUCLEIC ACIDS;

EID: 84924508257     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biotechadv.2015.02.004     Document Type: Review

References (164)

1. Aarts M., Liu Y., Liu L., Besshoh S., Arundine M., Gurd J.W., et al. Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions. Science 2002, 298:846-850.
2. Abbott N.J., Ronnback L., Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006, 7:41-53.
3. Adinolfi M. The permeability of the blood-CSF barrier during foetal life in man and rat and the effect of brain antibodies on the development of the CNS. Protein transmission through living membranes 1979, 349-364. Elsevier/North-Holland Biomedical Press, Amsterdam. W.A. Hemmings (Ed.).
4. Alvarez J.I., Dodelet-Devillers A., Kebir H., Ifergan I., Fabre P.J., Terouz S., et al. The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence. Science 2011, 334:1727-1731.
5. Arthur F.E., Shivers R.R., Bowman P.D. Astrocyte-mediated induction of tight junctions in brain capillary endothelium: an efficient in vitro model. Brain Res 1987, 433:155-159.
6. Balossier A., Dorner L., Emery E., Heese O., Mehdorn H.M., Menei P., et al. Incorporating BCNU wafers into malignant glioma treatment European case studies 2010, 30:195-204.
7. Bartanusz V., Jezova D., Alajajian B., Digicaylioglu M. The blood-spinal cord barrier: morphology and clinical implications. Ann Neurol 2011, 70:194-206.
8. Bechmann I., Priller J., Kovac A., Bontert M., Wehner T., Klett F.F., et al. Immune surveillance of mouse brain perivascular spaces by blood-borne macrophages. Eur J Neurosci 2001, 14:1651-1658.
9. Benedict C., Hallschmid M., Hatke A., Schultes B., Fehm H.L., Born J., et al. Intranasal insulin improves memory in humans. Psychoneuroendocrinology 2004, 29:1326-1334.
10. Bhaskar S., Tian F., Stoeger T., Kreyling W., de la Fuente J.M., Grazu V., et al. Multifunctional nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging. Part Fibre Toxicol 2010, 7:3.
11. Bichat F., Demeule M, Lawrence B, Raguin O, Sourzat B, Gabathuler R, et al. Enhanced drug delivery to brain tumours with a new paclitaxel-peptide conjugate. Eur J Cancer 2008, (Suppl. 6):139.
12. Bickel U., Yoshikawa T., Landaw E.M., Faull K.F., Pardridge W.M. Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery. Proc Natl Acad Sci U S A 1993, 90:2618-2622.
13. Boado R.J. Blood-brain barrier transport of non-viral gene and RNAi therapeutics. Pharm Res 2007, 24:1772-1787.
14. Boado R.J., Zhang Y., Zhang Y., Pardridge W.M. Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier. Biotechnol Bioeng 2007, 96:381-391.
15. Boado R.J., Zhang Y., Zhang Y., Xia C.F., Wang Y., Pardridge W.M. Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier. Biotechnol Bioeng 2008, 99:475-484.
16. Born J., Lange T., Kern W., McGregor G.P., Bickel U., Fehm H.L. Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 2002, 5:514-516.
17. Borsello T., Clarke P.G., Hirt L., Vercelli A., Repici M., Schorderet D.F., et al. A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat Med 2003, 9:1180-1186.
18. Burger C., Nash K., Mandel R.J. Recombinant adeno-associated viral vectors in the nervous system. Hum Gene Ther 2005, 16:781-791.
19. Chien A.J., Illi J.A., Ko A.H., Korn W.M., Fong L., Chen L.M., et al. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound paclitaxel for advanced solid malignancies. Clin Cancer Res 2009, 15:5569-5575.
20. Chodobski A., Zink B.J., Szmydynger-Chodobska J. Blood-brain barrier pathophysiology in traumatic brain injury. Transl Stroke Res 2011, 2:492-516.
21. Corchero J.L., Gasser B., Resina D., Smith W., Parrilli E., Vazquez F., et al. Unconventional microbial systems for the cost-efficient production of high-quality protein therapeutics. Biotechnol Adv 2013, 31:140-153.
22. da Cruz M.T., Cardoso A.L., de Almeida L.P., Simoes S., de Lima M.C. Tf-lipoplex-mediated NGF gene transfer to the CNS: neuronal protection and recovery in an excitotoxic model of brain injury. Gene Ther 2005, 12:1242-1252.
23. Daya S., Berns K.I. Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 2008, 21:583-593.
24. De R.R., Garcia A.A., Braschi C., Capsoni S., Maffei L., Berardi N., et al. Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice. Proc Natl Acad Sci U S A 2005, 102:3811-3816.
25. Deli M.A., Descamps L., Dehouck M.P., Cecchelli R., Joo F., Abraham C.S., et al. Exposure of tumor necrosis factor-alpha to luminal membrane of bovine brain capillary endothelial cells cocultured with astrocytes induces a delayed increase of permeability and cytoplasmic stress fiber formation of actin. J Neurosci Res 1995, 41:717-726.
26. Demeule M., Regina A., Che C., Poirier J., Nguyen T., Gabathuler R., et al. Identification and design of peptides as a new drug delivery system for the brain. J Pharmacol Exp Ther 2008, 324:1064-1072.
27. Demeule M., Regina A., Che C., Poirier J., Nguyen T., Gabathuler R., et al. Identification and design of peptides as a new drug delivery system for the brain 2008, 324:1064-1072.
28. Didier N., Romero I.A., Creminon C., Wijkhuisen A., Grassi J., Mabondzo A. Secretion of interleukin-1beta by astrocytes mediates endothelin-1 and tumour necrosis factor-alpha effects on human brain microvascular endothelial cell permeability. J Neurochem 2003, 86:246-254.
29. Domingo-Espin J., Vazquez E., Ganz J., Conchillo O., Garcia-Fruitos E., Cedano J., et al. Nanoparticulate architecture of protein-based artificial viruses is supported by protein-DNA interactions. Nanomedicine (Lond) 2011, 6:1047-1061.
30. Duque S., Joussemet B., Riviere C., Marais T., Dubreil L., Douar A.M., et al. Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther 2009, 17:1187-1196.
31. Dusserre N., Lessard C., Paquette N., Perron S., Poulin L., Tremblay M., et al. Encapsulation of foscarnet in liposomes modifies drug intracellular accumulation, in vitro anti-HIV-1 activity, tissue distribution and pharmacokinetics. AIDS 1995, 9:833-841.
32. Edelstein M.L., Abedi M.R., Wixon J. Gene therapy clinical trials worldwide to 2007-an update. J Gene Med 2007, 9:833-842.
33. Egleton R.D., Davis T.P. Development of neuropeptide drugs that cross the blood-brain barrier. NeuroRx 2005, 2:44-53.
34. el-Bacha R.S., Minn A. Drug metabolizing enzymes in cerebrovascular endothelial cells afford a metabolic protection to the brain. Cell Mol Biol 1999, 45:15-23.
35. Farrington G.K., Caram-Salas N., Haqqani A.S., Brunette E., Eldredge J., Pepinsky B., et al. A novel platform for engineering blood-brain barrier-crossing bispecific biologics. FASEB J 2014, 28:4764-4778.
36. Federici T., Taub J.S., Baum G.R., Gray S.J., Grieger J.C., Matthews K.A., et al. Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs. Gene Ther 2012, 19:852-859.
37. Ferrer-Miralles N., Vazquez E., Villaverde A. Membrane-active peptides for non-viral gene therapy: making the safest easier. Trends Biotechnol 2008, 26:267-275.
38. Ferrer-Miralles N., Rodríguez-Carmona E., Corchero J.L., García-Fruitós E., Vázquez E., Villaverde A. Engineering protein self-assembling in protein-based nanomedicines for drug delivery and gene therapy. Crit Rev Biotechnol 2013 Oct 9, [PMID: 24102113, Epub ahead of print].
39. Fioravanti J., Medina-Echeverz J., Ardaiz N., Gomar C., Parra-Guillen Z.P., Prieto J., et al. The fusion protein of IFN-alpha and Apolipoprotein A-I crosses the blood-brain barrier by a saturable transport mechanism 2012, 188:3988-3992.
40. Foust K.D., Nurre E., Montgomery C.L., Hernandez A., Chan C.M., Kaspar B.K. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 2009, 27:59-65.
41. Foust K.D., Wang X., McGovern V.L., Braun L., Bevan A.K., Haidet A.M., et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol 2010, 28:271-274.
42. Fu A., Zhou Q.H., Hui E.K., Lu J.Z., Boado R.J., Pardridge W.M. Intravenous treatment of experimental Parkinson's disease in the mouse with an IgG-GDNF fusion protein that penetrates the blood-brain barrier. Brain Res 2010, 1352:208-213.
43. Fu A.L., Zhou Q.H., Hui E.K.W., Lu J.Z., Boado R.J., Pardridge W.M. Intravenous treatment of experimental Parkinson's disease in the mouse with an IgG-GDNF fusion protein that penetrates the blood-brain barrier 2010, 1352:208-213.
44. Fu A.L., Hui E.K.W., Lu J.Z., Boado R.J., Pardridge W.M. Neuroprotection in stroke in the mouse with intravenous erythropoietin-Trojan horse fusion protein 2011, 1369:203-207.
45. Gabathuler R.A.G.K.M.L.C.Q.T.S.Y.J.s.W.V.T.Z.J.W.A. Development of a potential protein vector(NeuroTrans) to deliver drugs across the blood-brain barrier. Int Congr Ser 2005, 1277:171-184.
46. Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis 2010, 37:48-57.
47. Gabathuler R. An engineered peptide compound platform technology incorporating angiopep for crossing the BBB 2010, Humana Press Inc., 999 Riverview Dr, Ste 208, Totowa, NJ 07512-1165 USA.
48. Gessner A., Olbrich C., Schroder W., Kayser O., Muller R.H. The role of plasma proteins in brain targeting: species dependent protein adsorption patterns on brain-specific lipid drug conjugate (LDC) nanoparticles 2001, 214:87-91.
49. Ghose A.K., Viswanadhan V.N., Wendoloski J.J. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J Comb Chem 1999, 1:55-68.
50. Ginn S.L., Alexander I.E., Edelstein M.L., Abedi M.R., Wixon J. Gene therapy clinical trials worldwide to 2. J Gene Med 2013, 15:65-77.
51. Gozes I., Stewart A., Morimoto B., Fox A., Sutherland K., Schmeche D. Addressing Alzheimer's disease tangles: from NAP to AL-108. Curr Alzheimer Res 2009, 6:455-460.
52. Grassin-Delyle S., Buenestado A., Naline E., Faisy C., Blouquit-Laye S., Couderc L.J., et al. Intranasal drug delivery: an efficient and non-invasive route for systemic administration focus on opioids 2012, 134:366-379.
53. Gray S.J., Blake B.L., Criswell H.E., Nicolson S.C., Samulski R.J., McCown T.J., et al. Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). Mol Ther 2010, 18:570-578.
54. Gray S.J., Matagne V., Bachaboina L., Yadav S., Ojeda S.R., Samulski R.J. Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther 2011, 19:1058-1069.
55. Grieger J.C., Samulski R.J. Adeno-associated virus as a gene therapy vector: vector development, production and clinical applications. Adv Biochem Eng Biotechnol 2005, 99:119-145.
56. Hansen D.W., Stapelfeld A., Savage M.A., Reichman M., Hammond D.L., Haaseth R.C., et al. Systemic analgesic activity and delta-opioid selectivity in [2,6-dimethyl-Tyr1, D-Pen2, D-Pen5]enkephalin. J Med Chem 1992, 35:684-687.
57. Hanson L.R., Frey W.H. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci 2008, 9(Suppl. 3):S5.
58. Hanson M., Lobner D. In vitro neuronal cytotoxicity of latex and nonlatex orthodontic elastics. Am J Orthod Dentofacial Orthop 2004, 126:65-70.
59. Iliff J.J., Wang M., Liao Y., Plogg B.A., Peng W., Gundersen G.A., et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. Sci Transl Med 2012, 4:147ra111.
60. Janzer R.C., Raff M.C. Astrocytes induce blood-brain barrier properties in endothelial cells. Nature 1987, 325:253-257.
61. Jin K., Xie L., Childs J., Sun Y., Mao X.O., Logvinova A., et al. Cerebral neurogenesis is induced by intranasal administration of growth factors. Ann Neurol 2003, 53:405-409.
62. Karkan D., Pfeifer C., Vitalis T.Z., Arthur G., Ujiie M., Chen Q., et al. A unique carrier for delivery of therapeutic compounds beyond the blood-brain barrier. PLoS One 2008, 3:e2469.
63. Kilic E., Dietz G.P., Hermann D.M., Bahr M. Intravenous TAT-Bcl-Xl is protective after middle cerebral artery occlusion in mice. Ann Neurol 2002, 52:617-622.
64. Kilic U., Kilic E., Dietz G.P., Bahr M. Intravenous TAT-GDNF is protective after focal cerebral ischemia in mice. Stroke 2003, 34:1304-1310.
65. Kim W.K., Alvarez X., Fisher J., Bronfin B., Westmoreland S., McLaurin J., et al. CD163 identifies perivascular macrophages in normal and viral encephalitic brains and potential precursors to perivascular macrophages in blood. Am J Pathol 2006, 168:822-834.
66. Kim H.R., Andrieux K., Gil S., Taverna M., Chacun H., Desmaele D., et al. Translocation of poly(ethylene glycol-co-hexadecyl)cyanoacrylate nanoparticles into rat brain endothelial cells: role of apolipoproteins in receptor-mediated endocytosis. Biomacromolecules 2007, 8:793-799.
67. Kordower J.H., Charles V., Bayer R., Bartus R.T., Putney S., Walus L.R., et al. Intravenous administration of a transferrin receptor antibody-nerve growth factor conjugate prevents the degeneration of cholinergic striatal neurons in a model of Huntington disease. Proc Natl Acad Sci U S A 1994, 91:9077-9080.
68. Kratzer I., Wernig K., Panzenboeck U., Bernhart E., Reicher H., Wronski R., et al. Apolipoprotein A-I coating of protamine-oligonucleotide nanoparticles increases particle uptake and transcytosis in an in vitro model of the blood-brain barrier. J Control Release 2007, 117:301-311.
69. Kratzer I., Wernig K., Panzenboeck U., Bernhart E., Reicher H., Wronski R., et al. Apolipoprotein A-I coating of protamine-oligonucleotide nanoparticles increases particle uptake and transcytosis in an in vitro model of the blood-brain barrier 2007, 117:301-311.
70. Kroll R.A., Neuwelt E.A. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means 1998, 42:1083-1099.
71. Kumar P., Wu H., McBride J.L., Jung K.E., Kim M.H., Davidson B.L., et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 2007, 448:39-43.
72. Kurzrock R., Gabrail N., Chandhasin C., Moulder S., Smith C., Brenner A., et al. Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of Angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors 2012, 11:308-316.
73. Lee S.Y., Mattanovich D., Villaverde A. Systems metabolic engineering, industrial biotechnology and microbial cell factories. Microb Cell Fact 2012, 11:156.
74. Li T., Bourgeois J.P., Celli S., Glacial F., Le Sourd A.M., Mecheri S., et al. Cell-penetrating anti-GFAP VHH and corresponding fluorescent fusion protein VHH-GFP spontaneously cross the blood-brain barrier and specifically recognize astrocytes: application to brain imaging. FASEB J 2012, 26:3969-3979.
75. Liu X.F., Fawcett J.R., Hanson L.R., Frey W.H. The window of opportunity for treatment of focal cerebral ischemic damage with noninvasive intranasal insulin-like growth factor-I in rats. J Stroke Cerebrovasc Dis 2004, 13:16-23.
76. Ljubimova J.Y., Fujita M., Ljubimov A.V., Torchilin V.P., Black K.L., Holler E. Poly(malic acid) nanoconjugates containing various antibodies and oligonucleotides for multitargeting drug delivery. Nanomedicine (Lond) 2008, 3:247-265.
77. Lowenstein P.R. Crossing the rubicon. Nat Biotechnol 2009, 27:42-44.
78. Lu J.Z., Boado R.J., Hui E.K., Zhou Q.H., Pardridge W.M. Expression in CHO cells and pharmacokinetics and brain uptake in the Rhesus monkey of an IgG-iduronate-2-sulfatase fusion protein. Biotechnol Bioeng 2011, 108:1954-1964.
79. Maggie J., Hsiang-Fa L., Sing-Ming C., Yi-Ju K., Li-Wen C. Peptide for transmigration across brain blood barrier and delivery systems comprising the same 2010, [12/979, 804[US2011/0165079 A1]. US].
80. Malcor J.D., Payrot N., David M., Faucon A., Abouzid K., Jacquot G., et al. Chemical optimization of new ligands of the low-density lipoprotein receptor as potential vectors for central nervous system targeting 2012, 55:2227-2241.
81. Mamot C., Drummond D.C., Noble C.O., Kallab V., Guo Z., Hong K., et al. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res 2005, 65:11631-11638.
82. Mandel R.J., Manfredsson F.P., Foust K.D., Rising A., Reimsnider S., Nash K., et al. Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders. Mol Ther 2006, 13:463-483.
83. Mastrobattista E., van der Aa M.A., Hennink W.E., Crommelin D.J. Artificial viruses: a nanotechnological approach to gene delivery. Nat Rev Drug Discov 2006, 5:115-121.
84. Matsuoka Y., Jouroukhin Y., Gray A.J., Ma L., Hirata-Fukae C., Li H.F., et al. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther 2008, 325:146-153.
85. McCown T.J. Adeno-associated virus (AAV) vectors in the CNS. Curr Gene Ther 2005, 5:333-338.
86. Negro-Demontel M.L., Saccardo P., Giacomini C., Yáñez-Muñoz R.J., Ferrer-Miralles N., Vazquez E., et al. Comparative analysis of lentiviral vectors and modular protein nanovectors for traumatic brain injury gene therapy. Mol Ther Methods Clin Dev 2014, 1:14047.
87. Niewoehner J., Bohrmann B., Collin L., Urich E., Sade H., Maier P., et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron 2014, 81:49-60.
88. Olbrich C., Gessner A., Kayser O., Muller R.H. Lipid-drug-conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate. J Drug Target 2002, 10:387-396.
89. Pardridge W.M. Intravenous, non-viral RNAi gene therapy of brain cancer. Expert Opin Biol Ther 2004, 4:1103-1113.
90. Pardridge W.M. Molecular Trojan horses for blood-brain barrier drug delivery. Curr Opin Pharmacol 2006, 6:494-500.
91. Pardridge W.M., Boado R.J. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier 2012, Elsevier Academic Press Inc., San Diego.
92. Park T.E., Singh B., Li H., Lee J.Y., Kang S.K., Choi Y.J., et al. Enhanced BBB permeability of osmotically active poly(mannitol-co-PEI) modified with rabies virus glycoprotein via selective stimulation of caveolar endocytosis for RNAi therapeutics in Alzheimer's disease. Biomaterials 2015, 38:61-71.
93. Peluffo H., Aris A., Acarin L., Gonzalez B., Villaverde A., Castellano B. Nonviral gene delivery to the central nervous system based on a novel integrin-targeting multifunctional protein. Hum Gene Ther 2003, 14:1215-1223.
94. Peluffo H., Acarin L., Aris A., Gonzalez P., Villaverde A., Castellano B., et al. Neuroprotection from NMDA excitotoxic lesion by Cu/Zn superoxide dismutase gene delivery to the postnatal rat brain by a modular protein vector. BMC Neurosci 2006, 7:35.
95. Peluffo H., li-Ruiz D., Ejarque-Ortiz A., Heras-Alvarez V., Comas-Casellas E., Martinez-Barriocanal A., et al. Overexpression of the immunoreceptor CD300f has a neuroprotective role in a model of acute brain injury. Brain Pathol 2012, 22(3):318-328.
96. Poduslo J.F., Curran G.L. Increased permeability across the blood-nerve barrier of albumin glycated in vitro and in vivo from patients with diabetic polyneuropathy. Proc Natl Acad Sci U S A 1992, 89:2218-2222.
97. Polt R., Porreca F., Szabo L.Z., Bilsky E.J., Davis P., Abbruscato T.J., et al. Glycopeptide enkephalin analogues produce analgesia in mice: evidence for penetration of the blood-brain barrier. Proc Natl Acad Sci U S A 1994, 91:7114-7118.
98. Prades R., Guerrero S., Araya E., Molina C., Salas E., Zurita E., et al. Delivery of gold nanoparticles to the brain by conjugation with a peptide that recognizes the transferrin receptor. Biomaterials 2012, 33:7194-7205.
99. Prades R., Guerrero S., Araya E., Molina C., Salas E., Zurita E., et al. Delivery of gold nanoparticles to the brain by conjugation with a peptide that recognizes the transferrin receptor 2012, 33:7194-7205.
100. Qiao R., Jia Q., Huwel S., Xia R., Liu T., Gao F., et al. Receptor-mediated delivery of magnetic nanoparticles across the blood-brain barrier. ACS Nano 2012, 6:3304-3310.
101. Qiao R.R., Jia Q.J., Huwel S., Xia R., Liu T., Gao F.B., et al. Receptor-mediated delivery of magnetic nanoparticles across the blood-brain barrier 2012, 6:3304-3310.
102. Rao K.S., Ghorpade A., Labhasetwar V. Targeting anti-HIV drugs to the CNS. Expert Opin Drug Deliv 2009, 6:771-784.
103. Re F., Cambianica I., Sesana S., Salvati E., Cagnotto A., Salmona M., et al. Functionalization with ApoE-derived peptides enhances the interaction with brain capillary endothelial cells of nanoliposomes binding amyloid-beta peptide 2011, 156:341-346.
104. Reese T.S., Karnovsky M.J. Fine structural localization of a blood-brain barrier to exogenous peroxidase. J Cell Biol 1967, 34:207-217.
105. Reukov V., Maximov V., Vertegel A. Proteins conjugated to poly(butyl cyanoacrylate) nanoparticles as potential neuroprotective agents. Biotechnol Bioeng 2011, 108:243-252.
106. Reukov V., Maximov V., Vertegel A. Proteins conjugated to poly(butyl cyanoacrylate) nanoparticles as potential neuroprotective agents 2011, 108:243-252.
107. Rodriguez-Carmona E., Villaverde A. Nanostructured bacterial materials for innovative medicines. Trends Microbiol 2010, 18:423-430.
108. Rosenberg G.A. Neurological diseases in relation to the blood-brain barrier. J Cereb Blood Flow Metab 2012, 32:1139-1151.
109. Ross T.M., Martinez P.M., Renner J.C., Thorne R.G., Hanson L.R., Frey W.H. Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis. J Neuroimmunol 2004, 151:66-77.
110. Rousselle C., Clair P., Smirnova M., Kolesnikov Y., Pasternak G.W., Gac-Breton S., et al. Improved brain uptake and pharmacological activity of dalargin using a peptide-vector-mediated strategy. J Pharmacol Exp Ther 2003, 306:371-376.
111. Rubin L.L., Staddon J.M. The cell biology of the blood-brain barrier. Annu Rev Neurosci 1999, 22:11-28.
112. Schnyder A., Huwyler J. Drug transport to brain with targeted liposomes. NeuroRx 2005, 2:99-107.
113. Schnyder A., Huwyler J. Drug transport to brain with targeted liposomes 2005, 2:99-107.
114. Song B.W., Vinters H.V., Wu D., Pardridge W.M. Enhanced neuroprotective effects of basic fibroblast growth factor in regional brain ischemia after conjugation to a blood-brain barrier delivery vector. J Pharmacol Exp Ther 2002, 301:605-610.
115. Spencer B.J., Verma I.M. Targeted delivery of proteins across the blood-brain barrier. Proc Natl Acad Sci U S A 2007, 104:7594-7599.
116. Spitzenberger T.J., Heilman D., Diekmann C., Batrakova E.V., Kabanov A.V., Gendelman H.E., et al. Novel delivery system enhances efficacy of antiretroviral therapy in animal model for HIV-1 encephalitis. J Cereb Blood Flow Metab 2007, 27:1033-1042.
117. Steiniger S.C., Kreuter J., Khalansky A.S., Skidan I.N., Bobruskin A.I., Smirnova Z.S., et al. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer 2004, 109:759-767.
118. Stewart P.A., Hayakawa E.M. Interendothelial junctional changes underlie the developmental 'tightening' of the blood-brain barrier. Brain Res 1987, 429:271-281.
119. Tao Y.H., Han J.F., Dou H.Y. Brain-targeting gene delivery using a rabies virus glycoprotein peptide modulated hollow liposome: bio-behavioral study 2012, 22:11808-11815.
120. Tian X.H., Wei F., Wang T.X., Wang D., Wang J., Lin X.N., et al. Blood-brain barrier transport of Tat peptide and polyethylene glycol decorated gelatin-siloxane nanoparticle 2012, 68:94-96.
121. Tonra J.R. Cerebellar susceptibility to experimental autoimmune encephalomyelitis in SJL/J mice: potential interaction of immunology with vascular anatomy. Cerebellum 2002, 1:57-68.
122. Tosi G., Costantino L., Rivasi F., Ruozi B., Leo E., Vergoni A.V., et al. Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123. J Control Release 2007, 122:1-9.
123. Towne C., Raoul C., Schneider B.L., Aebischer P. Systemic AAV6 delivery mediating RNA interference against SOD1: neuromuscular transduction does not alter disease progression in fALS mice. Mol Ther 2008, 16:1018-1025.
124. Tsai S.J. Peripheral administration of brain-derived neurotrophic factor to Rett syndrome animal model: a possible approach for the treatment of Rett syndrome 2012, 18:HY33-HY36.
125. Ulbrich K., Hekmatara T., Herbert E., Kreuter J. Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur J Pharm Biopharm 2009, 71:251-256.
126. Ulbrich K., Knobloch T., Kreuter J. Targeting the insulin receptor: nanoparticles for drug delivery across the blood-brain barrier (BBB). J Drug Target 2011, 19:125-132.
127. + cell targeting with T22-empowered protein-only nanoparticles. Int J Nanomedicine 2012, 7:4533-4544.
128. Unzueta U., Ferrer-Miralles N., Cedano J., Zikung X., Pesarrodona M., Saccardo P., et al. Non-amyloidogenic peptide tags for the regulatable self-assembling of protein-only nanoparticles. Biomaterials 2012, 33:8714-8722.
129. Unzueta U., Saccardo P., Domingo-Espin J., Cedano J., Conchillo-Sole O., Garcia-Fruitos E., et al. Sheltering DNA in self-organizing, protein-only nano-shells as artificial viruses for gene delivery. Nanomedicine 2014, 10:535-541.
130. Van D.S., Bronselaer A., Nielandt J., Stalmans S., Wynendaele E., Audenaert K., et al. Brainpeps: the blood-brain barrier peptide database. Brain Struct Funct 2012, 217:687-718.
131. Vazquez E., Villaverde A. Engineering building blocks for self-assembling protein nanoparticles. Microb Cell Fact 2010, 9:101.
132. Vazquez E., Villaverde A. Microbial biofabrication for nanomedicine: biomaterials, nanoparticles and beyond. Nanomedicine (Lond) 2013, 8:1895-1898.
133. Vazquez E., Ferrer-Miralles N., Villaverde A. Peptide-assisted traffic engineering for nonviral gene therapy. Drug Discov Today 2008, 13:1067-1074.
134. Vazquez E., Ferrer-Miralles N., Mangues R., Corchero J.L., Schwartz S., Villaverde A. Modular protein engineering in emerging cancer therapies. Curr Pharm Des 2009, 15:893-916.
135. Vazquez E., Roldan M., Diez-Gil C., Unzueta U., Domingo-Espin J., Cedano J., et al. Protein nanodisk assembling and intracellular trafficking powered by an arginine-rich (R9) peptide. Nanomedicine (Lond) 2010, 5:259-268.
136. Wade L.A., Katzman R. Synthetic amino acids and the nature of L-DOPA transport at the blood-brain barrier. J Neurochem 1975, 25:837-842.
137. Wagner S., Zensi A., Wien S.L., Tschickardt S.E., Maier W., Vogel T., et al. Uptake mechanism of ApoE-modified nanoparticles on brain capillary endothelial cells as a blood-brain barrier model 2012, 7.
138. Wang J.X., Sun X., Zhang Z.R. Enhanced brain targeting by synthesis of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine and incorporation into solid lipid nanoparticles. Eur J Pharm Biopharm 2002, 54:285-290.
139. White E., Bienemann A., Pugh J., Castrique E., Wyatt M., Taylor H., et al. An evaluation of the safety and feasibility of convection-enhanced delivery of carboplatin into the white matter as a potential treatment for high-grade glioma 2012, 108:77-88.
140. White E., Bienemann A., Taylor H., Hopkins K., Cameron A., Gill S. A phase I trial of carboplatin administered by convection-enhanced delivery to patients with recurrent/progressive glioblastoma multiforme 2012, 33:320-331.
141. Witt K.A., Huber J.D., Egleton R.D., Roberts M.J., Bentley M.D., Guo L., et al. Pharmacodynamic and pharmacokinetic characterization of poly(ethylene glycol) conjugation to met-enkephalin analog [D-Pen2, D-Pen5]-enkephalin (DPDPE). J Pharmacol Exp Ther 2001, 298:848-856.
142. Wolburg H., Lippoldt A. Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul Pharmacol 2002, 38:323-337.
143. Wolf D.A., Hanson L.R., Aronovich E.L., Nan Z., Low W.C., Frey W.H., et al. Lysosomal enzyme can bypass the blood-brain barrier and reach the CNS following intranasal administration 2012, 106:131-134.
144. Wu D., Pardridge W.M. Central nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system. J Pharmacol Exp Ther 1996, 279:77-83.
145. Wu D., Pardridge W.M. Neuroprotection with noninvasive neurotrophin delivery to the brain. Proc Natl Acad Sci U S A 1999, 96:254-259.
146. Xia H., Mao Q., Davidson B.L. The HIV Tat protein transduction domain improves the biodistribution of beta-glucuronidase expressed from recombinant viral vectors. Nat Biotechnol 2001, 19:640-644.
147. Yang W.L., Huo T.Y., Barth R.F., Gupta N., Weldon M., Grecula J.C., et al. Convection enhanced delivery of carboplatin in combination with radiotherapy for the treatment of brain tumors 2011, 101:379-390.
148. Yao H., Wang K., Wang Y., Wang S., Li J., Lou J., et al. Enhanced blood-brain barrier penetration and glioma therapy mediated by a new peptide modified gene delivery system. Biomaterials 2014, 37C:345-352.
149. Yazaki T., Ahmad S., Chahlavi A., Zylber-Katz E., Dean N.M., Rabkin S.D., et al. Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide. Mol Pharmacol 1996, 50:236-242.
150. Yemisci M., Caban S., Gursoy-Ozdemir Y., Lule S., Novoa-Carballal R., Riguera R., et al. Systemically administered brain-targeted nanoparticles transport peptides across the blood-brain barrier and provide neuroprotection. J Cereb Blood Flow Metab 2014, [Epub ahead of print]. 10.1038/jcbfm.2014.220.
151. Yu Y.P., Xu Q.Q., Zhang Q., Zhang W.P., Zhang L.H., Wei E.Q. Intranasal recombinant human erythropoietin protects rats against focal cerebral ischemia. Neurosci Lett 2005, 387:5-10.
152. Yu Y.J., Zhang Y., Kenrick M., Hoyte K., Luk W., Lu Y., et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med 2011, 3:84ra44.
153. Yue J., Liu S., Wang R., Hu X., Xie Z., Huang Y., et al. Fluorescence-labeled immunomicelles: preparation, in vivo biodistribution, and ability to cross the blood-brain barrier 2012, 12:1209-1219.
154. Zensi A., Begley D., Pontikis C., Legros C., Mihoreanu L., Wagner S., et al. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones 2009, 137:78-86.
155. Zensi A., Begley D., Pontikis C., Legros C., Mihoreanu L., Buchel C., et al. Human serum albumin nanoparticles modified with apolipoprotein A-I cross the blood-brain barrier and enter the rodent brain. J Drug Target 2010, 18:842-848.
156. Zhang Y., Pardridge W.M. Neuroprotection in transient focal brain ischemia after delayed intravenous administration of brain-derived neurotrophic factor conjugated to a blood-brain barrier drug targeting system. Stroke 2001, 32:1378-1384.
157. Zhang Y., Lee H.J., Boado R.J., Pardridge W.M. Receptor-mediated delivery of an antisense gene to human brain, cancer cells 2002, 4:183-194.
158. Zhang Y., Calon F., Zhu C., Boado R.J., Pardridge W.M. Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. Hum Gene Ther 2003, 14:1-12.
159. Zhang Y., Schlachetzki F., Zhang Y.F., Boado R.J., Pardridge W.M. Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specific promoter. Hum Gene Ther 2004, 15:339-350.
160. Zhang Y., Zhang Y.F., Bryant J., Charles A., Boado R.J., Pardridge W.M. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin Cancer Res 2004, 10:3667-3677.
161. Zhang Y., Wang Y., Boado R.J., Pardridge W.M. Lysosomal enzyme replacement of the brain with intravenous non-viral gene transfer. Pharm Res 2008, 25:400-406.
162. Zhou Q.H., Fu A., Boado R.J., Hui E.K., Lu J.Z., Pardridge W.M. Receptor-mediated abeta amyloid antibody targeting to Alzheimer's disease mouse brain. Mol Pharm 2011, 8:280-285.
163. Zhou Q.H., Hui E.K., Lu J.Z., Boado R.J., Pardridge W.M. Brain penetrating IgG-erythropoietin fusion protein is neuroprotective following intravenous treatment in Parkinson's disease in the mouse. Brain Res 2011, 1382:315-320.
164. Zhu J.H., Jiang Y.J., Xu G.L., Liu X.F. Intranasal administration: a potential solution for cross-BBB delivering neurotrophic factors 2012, 27:537-548.